ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

Relay Therapeutics, Inc. has bolstered its case that more precise targeting of fibroblast growth factor receptor 2 (FGFR2) can overcome the limitations of existing FGFR inhibitors in FGFR2-altered cholangiocarcinoma by sidestepping the off-target toxicities associated those drugs, particularly hyperphosphatemia and diarrhea. While the dataset includes only a small number of patients and the median duration of response remains unreached, there were encouraging signs, including a high response rate.

Relay presented the highly anticipated data at the European Society for Medical Oncology meeting on 11 September for RLY-4008, its selective, oral small molecule FGFR2 inhibitor, at the pivotal dose of 70mg daily. While the data were in only 17 patients, they showed a high degree of efficacy with an adverse event profile that was within expectations and that did not include grade 4 or fatal events